GSA Capital Partners LLP Buys New Shares in Nuvation Bio Inc. (NYSE:NUVB)

GSA Capital Partners LLP purchased a new position in Nuvation Bio Inc. (NYSE:NUVB) during the 3rd quarter, Holdings Channel reports. The firm purchased 74,932 shares of the company’s stock, valued at approximately $172,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Nuvation Bio by 3.0% in the first quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock valued at $27,424,000 after buying an additional 219,533 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Nuvation Bio by 551.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock valued at $4,932,000 after acquiring an additional 1,146,794 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Nuvation Bio by 415.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock worth $2,975,000 after acquiring an additional 820,669 shares during the period. Panagora Asset Management Inc. grew its holdings in shares of Nuvation Bio by 198.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 633,676 shares of the company’s stock worth $1,850,000 after purchasing an additional 421,563 shares in the last quarter. Finally, Algert Global LLC grew its holdings in shares of Nuvation Bio by 281.0% during the 2nd quarter. Algert Global LLC now owns 426,603 shares of the company’s stock worth $1,246,000 after purchasing an additional 314,635 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Analysts Set New Price Targets

NUVB has been the subject of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Nuvation Bio in a research report on Thursday, November 7th. Royal Bank of Canada raised their price objective on shares of Nuvation Bio from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, HC Wainwright decreased their target price on shares of Nuvation Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Nuvation Bio presently has an average rating of “Buy” and a consensus price target of $6.60.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, Director Robert Mashal purchased 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was acquired at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now directly owns 100,000 shares of the company’s stock, valued at $220,000. This represents a ? increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.07% of the company’s stock.

Nuvation Bio Price Performance

Shares of NYSE:NUVB opened at $2.80 on Monday. The business’s fifty day moving average price is $2.51 and its two-hundred day moving average price is $2.89. Nuvation Bio Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $4.16. The stock has a market capitalization of $942.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.35.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $0.73 million for the quarter. Research analysts expect that Nuvation Bio Inc. will post -0.4 EPS for the current fiscal year.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.